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disease and strokes), and for myocardial infarctions (MI) spe-
ciﬁcally, occurring during the use of the initially prescribed
statin were compared between different statins using multivari-
ate Cox-regression analysis. RESULTS: Included new statin
users started with simvastatin (32824 (35%)), atorvastatin
(30849 (33%)), pravastatin (19652 (21%)), or rosuvastatin
(8710 (9%)). Average doses were 23 mg, 19 mg, 35 mg and
11 mg respectively. Thirty-ﬁve (percent) were considered to be
at increased risk of cardiovascular events due to pre-existing
CVD or diabetes. The median duration of follow up and initial
statin therapy were two years and 48 weeks respectively. The
incidence per 100 person years of fatal and non-fatal CVD
and MI respectively were 3.2 and 0.4 for rosuvastatin, 4.5 and
0.6 for atorvastatin, 4.1 and 0.7 for simvastatin, and 6.5 and
1.0 for pravastatin. Different multivariate models and adjust-
ment methods were used to study whether the observed
differences could be explained by bias or confounding. None of
these adjustments or models altered the observed risk differ-
ences substantially. CONCLUSION: We observed substantial
differences in incidence rates of hospitalisations for cardiovas-
cular events between users of different statins, independent
from dosing and preferences in prescribing of statins. The
lowest incidence of hospitalizations due to cardiovascular
events were observed among users of rosuvastatin followed by
atorvastatin, simvastatin and pravastatin. These ﬁndings
suggest that the greater LDL-C reductions offered by rosuvas-
tatin may translate into additional beneﬁts in lower rates of
cardiovascular events.
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OBJECTIVES: 1.) To ﬁnd efﬁciency Hierarchical Stepwise Mul-
tiple Regression Analysis model that predict diastolic blood
pressure. 2.) To ﬁnd correlation between calories burnt by exer-
cise, compliance, eating behavior score, hypertension knowl-
edge and diastolic blood pressure. METHODS: A cross-
sectional clinical and survey study by face to face interview
with questionnaire was employed to investigate relationship
between health behavior factors namely—calories burnt by
exercise, compliance, eating behavior score, smoking, drinking,
demographic data and diastolic blood pressure of 200 hyper-
tension patients at Adisorn Hospital selected by convenient
sampling. RESULTS: Total sample size (n = 200, 100%) of
hypertension patients, mostly 113 (56.50%) were female,
87 (43.50%) were male with average age 57.29  13.16
years, Average BMI 27.52  3.84, Average total calories burnt
per week 1749.68  3948.43, Average compliance score
7.85  2.12, Average hypertension knowledge score 7.06 
0.58, Average eating behavior score 6.91  1.97, and average
Diastolic 94.11  11.11. Compliance score and hypertension
knowledge had signiﬁcantly correlated with Diastolic (r = 0.97,
-0.13, p < 0.01). Hierarchical stepwise Multiple Regression
Analysis conﬁrmed that 3 factors—calories burnt by exercise,
compliance score and age were signiﬁcantly predictors of Dias-
tolic (Beta = 0.56, 0,42, 0.05, p < 0.01, R Square = 0.86).
CONCLUSION: Hierarchical Stepwise Multiple Regression
Analysis conﬁrmed that calories burnt by exercise, compliance
and age were three signiﬁcantly factors predicted diastolic
blood pressure.
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OBJECTIVES: To evaluate the degree of interrelation among
cardiovascular risk factors (CVRF), and routine achievement of
some therapeutic goals for modiﬁable CVRF in primary care
settings. METHODS: Multicentric-retrospective study. Data
were obtained from 5 primary care setting clinic records (patients
>30 years old) during 2006. Patients were divided into 8 groups,
including combinations of the three main modiﬁable CVRF. Cri-
teria: NCEP-ATP III modiﬁed. Main measures: cardiovascular/
general diagnostics, cardiovascular events (CVE), clinical
parameters (systolic and diastolic blood pressure, cholesterol
levels, LDLc levels, etc) and costs (semi ﬁxed/variable, tests,
derivation, drugs). ANCOVA analyses were developed (Bonfer-
roni adjust) to correct the model. SPSS program was used. A
signiﬁcance level of , p < 0.05 was used RESULTS: In total,
57,025 patients were studied, age: 54.3  16,2 years old, 54.8%
women; CVE: 8.8%. Distribution by groups: a) population:
55.3% (n = 31,554; age: 47.2  14.1 years old; women: 55.7%;
ECV: 3.1%), b) Hypertension (HT): 11,6% (n = 6627; age:
66,9  13,8 years old; women: 57.4%; CVE: 14.4%), c) Diabe-
tes Mellitus DM): 2.6% (n = 1465; age: 60.1  16.4 years old;
women: 44.4%; CVE: 16.8%), d) Dyslipidemia (DL): 13.7%
(n = 7811; age: 55.2  13.2 years old; women: 50.5%; CVE:
8.2%), e) HT-DM: 2.8% (n = 1624; age: 71.2  11.8 years
old; women: 55.5%; CVE: 25.4%), f) HT-DL: 8.3% (n = 4707;
age: 66.5  11.7 years old; women: 57.3%; ECV: 19.1%), g)
DM-DL: 1.9% (n = 1058; age: 63.5  11.8 years old; women:
41.7%; ECV: 23.3%) y h) HT-DM-DL: 3.8% (n = 2179; age:
69.1  10.2 years old; women: 55.5%; CVE: 30.6%), p < 0.001.
DM-DL and HT-DM-DL groups had the worst metabolic
controls. All components of costs were higher in the HT-
DM and HT-DM-DL groups; 1543.60  1232.33 y 1739.07 
1192.35€, respectively (p < 0.001). CONCLUSION: Diabetes
mellitus is the main risk factor (greater presence in CVE) and is
associated with worse metabolic status and higher cost of care.
Achievement of established therapeutic goals must be improved
in primary care.
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OBJECTIVES: The aim of our study is to analyse the validity
of administrative data and the appropriateness, accessibility
and effectiveness of acute myoardial infarction (AMI) care.
METHODS: Data derive from the nationwide database of the
National Health Insurance Fund Administration (OEP). Our
tudy includes patients admitted to a hospital between 2000 and
2005 due to AMI (ICD 10, I21 or I22) or were treated by
reperfusion or revascularisation therapy (PCI, thrombolysis,
CABG—intervention group). The mortality data was derived
from death certiﬁcates. We analysed the role of risk factors by
logistic regression. RESULTS: From 2000 until 2005 the number
of AMI cases has increased from 14089 to 16296 (n = 92902)
while the 30-day mortality of AMI cases decreased from 20.9%
to 19.2% (P < 0.001). In 2000, 30.3% of the AMI cases were
treated with PCI, thrombolysis or CABG, this proportion
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increased to 42.6% by 2005. In 2000, 89.5% of all AMI
patients was treated with thrombolysis as primary intervention,
7.8% underwent PCI, and 2.6% CABG; by 2005 these percent-
ages changed to 21.1%, 73.1%, and 5.8% respectively. We
compared the 30-day and one year mortality by intervention
groups. In 2005 without any intervention it was 27.5% vs
37.8% (30 days and 1 year), in the PCI group 6.1% vs 9.7%,
in the thrombolysis group 14.8% vs 18.7% and in the CABG
group 6.4% vs 12.3%. The 30-day mortality is independent of
gender but depends on age. The chance of 30-day survival
decreases due to diabetes and cancer (OR: 0.885 and 0.60,
respectively), shock (OR: 0.06) and resuscitation (OR: 0.07).
Survival is signiﬁcantly better in case of hypertension (OR: 1.4).
CONCLUSION: Administrative data proved to be appropriate
tools to develop quality indicators, thus its results can be very
useful in improving health care.
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OBJECTIVES: To quantify and qualify the risk of major bleed-
ing associated with the use of antibiotic drugs during coumarin
anticoagulant therapy in daily practice. METHODS: Data
for this retrospective cohort study were obtained from the
PHARMO Record Linkage System, including, among others,
linked drug-dispensing records and hospital records for over
three million individuals in deﬁned areas of The Netherlands.
The study cohort included all users of acenocoumarol or phen-
procoumon, aged 40–80 years, for the period 1996–2004. All
patients were followed until the end of their last coumarin dis-
pensing, hospitalisation for bleeding, death, or end of study
period. Number of days on coumarins alone, and number of
days on coumarins in combination with each antibiotic drug
during follow-up, were determined for each patient. We analy-
sed antibiotic drugs for which at least ﬁve patients experienced
a bleeding at least two weeks after anticoagulant therapy com-
menced, and which fell within the risk period of a single anti-
biotic drug. RESULTS: Respectively, 52,102 acenocoumarol
and 7,885 phenprocoumon users met the inclusion criteria for
the study cohort and contributed 139,159 patient-years of
follow-up. During follow-up 838 patients (1.4%) were hospit-
alised for bleeding while taking coumarins. The antibiotic drugs
for which at least ﬁve coumarin users had a bleeding were
doxycycline, amoxicillin, amoxicillin/clavulanic acid, ciprof-
loxacin and cotrimoxazole. Each of these antibiotic drugs was
associated with an increased risk of bleeding. Incidence rates
ranged from 5.2 major bleedings per 10,000 doxycycline-
dispensings to 11.2 major bleedings per 10,000 cotrimoxazole-
dispensings during coumarin use. Corresponding relative
risks for major bleeding, adjusted for gender and age, ranged
from 2.6 (95% CI 1.4–4.8) for doxycycline to 5.3 (95% CI
2.4–11.8) for cotrimoxazole. CONCLUSION: Doxycycline,
amoxicillin, amoxicillin/clavulanic acid, ciproﬂoxacin and cot-
rimoxazole are the main antibiotic drugs associated with an
increased risk of major bleeding during coumarin anticoagulant
therapy in daily practice.
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OBJECTIVES: To characterize epidemiological risk factors,
review clinical outcomes, and overall costs associated with treat-
ing bleeding related to cardiac surgery, and identify areas for
further research. METHODS: A systematic literature search was
performed (1996-March 2007) using terms designed to identify
publications describing epidemiology and associated risk factors,
clinical outcomes, and economic impact of bleeding in cardiac
surgery patients. Studies were identiﬁed through electronic Med-
line® and PubMed® searches. Manual review of bibliographies
within these papers allowed identiﬁcation of additional articles.
RESULTS: A total of 36 (epidemiology: n = 13, clinical out-
comes: n = 14, and economic burden: n = 9) papers [manual
search: n = 12] were included for review. Incidence of bleeding
associated with major cardiac surgical procedures varied widely,
ranging from 0.4%–19.0%, partly attributable to the types of
cardiac operations as well as to differences in the deﬁnition of
bleeding. Pre-operative smaller body mass index, use of anti-
thrombotic drugs, nonelective surgery, increased age, and redo
procedures were associated with bleeding, while embolic events
were found to be major complications. Costs associated with
bleeding requiring transfusion ranged from $397 (blood prod-
ucts only) to $10,225 per patient (all treatment costs), with
hospital LOS as the major cost contributor. Mean cost of open-
heart surgeries [including coronary artery bypass graft (CABG)
and valve replacements] range from $25,057 to $79,795, with
patients undergoing CABG found to have an incremental cost of
$3,866 associated with bleeding. Primary pharmacological treat-
ments for bleeding among cardiac surgery patients included anti-
ﬁbrinolytics and procoagulants. CONCLUSION: Post-operative
bleeding remains a central clinical outcome in cardiac surgery
with signiﬁcant economic impact despite improvements in peri-
operative bleeding management. Sufﬁcient information on recent
cost estimates as well as differences in bleeding costs associated
with various cardiac procedures is lacking. Further research
investigating the economic consequences of bleeding associated
with cardiac surgery is warranted.
CARDIOVASCULAR DISEASE—Cost Studies
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OBJECTIVES: Introduction. The polish system of medication
reimbursement is based on positive list. The government decides
which medication could be reimbursed by adding or removing it
from the list. Additional tool for reimbursement control is the
“medication refund limit” (MRL). The same MRL per DDD is
set for each INN separately or for group of medication, which
have the same indication, form and dose. The payer (National
Fund of Health) partially refunds the cost of medication below
the MRL. The difference between the MRL and price is paid by
patient. In 2006 the government changed the MRL and ofﬁcial
prices for some medication. The aim is to assess the impact of
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